2.2.2017 Secondary announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Neos Therapeutics
Symbol: NEOS
Price: Last trade $5.80
Description: Re-offer $5.00
Trade Date: 2/3
Shares: 5 million
Underwriter(s)Cowen & Co., BMO Capital Markets
Rating=Subscription Needed

Company: The Rubicon Project-BLOCK
Symbol: RUBI
Price: Last trade $8.48
Description: Re-offer $7.70
Trade Date: 2/3
Shares: 3.9 million
Underwriter(s)Goldman Sachs
Rating=Subscription Needed